Selling and Marketing Expense in USD of HERON THERAPEUTICS, INC. /DE/ from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Heron Therapeutics, Inc. /De/ quarterly/annual Selling and Marketing Expense history and growth rate from 2014 to Q3 2025.
  • Heron Therapeutics, Inc. /De/ Selling and Marketing Expense for the quarter ending September 30, 2025 was $12.9M, a 18% increase year-over-year.
  • Heron Therapeutics, Inc. /De/ Selling and Marketing Expense for the twelve months ending September 30, 2025 was $47.9M, a 0.97% decline year-over-year.
  • Heron Therapeutics, Inc. /De/ annual Selling and Marketing Expense for 2024 was $47.1M, a 30.4% decline from 2023.
  • Heron Therapeutics, Inc. /De/ annual Selling and Marketing Expense for 2023 was $67.6M, a 18% decline from 2022.
  • Heron Therapeutics, Inc. /De/ annual Selling and Marketing Expense for 2022 was $82.5M, a 5.35% decline from 2021.
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Growth (%)
Selling and Marketing Expense, Annual (USD)
Selling and Marketing Expense, YoY Annual Growth (%)

HERON THERAPEUTICS, INC. /DE/ Quarterly Selling and Marketing Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $47.9M $12.9M +$1.97M +18% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $45.9M $11.6M -$2.04M -15% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-08
Q1 2025 $48M $12.3M +$869K +7.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q4 2024 $47.1M $11.1M -$1.27M -10.3% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $48.4M $11M -$1.98M -15.3% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $50.3M $13.6M -$7.59M -35.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-08
Q1 2024 $57.9M $11.4M -$9.71M -45.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q4 2023 $67.6M $12.3M -$5.45M -30.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $73.1M $13M -$5.42M -29.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $78.5M $21.2M -$1.73M -7.56% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $80.2M $21.2M -$2.27M -9.68% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $82.5M $17.8M -$6.71M -27.4% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $89.2M $18.4M -$6.83M -27.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $96.1M $22.9M +$688K +3.09% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $95.4M $23.4M +$8.19M +53.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $87.2M $24.5M +$8.93M +57.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $78.2M $25.2M +$12.7M +101% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $65.6M $22.3M +$6.66M +42.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $58.9M $15.2M -$4.96M -24.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $63.9M $15.6M -$4.87M -23.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-24
Q3 2020 $68.7M $12.5M -$4.46M -26.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $73.2M $15.6M -$8.06M -34.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $81.2M $20.2M -$8.52M -29.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $89.8M $20.4M +$463K +2.32% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 $89.3M $17M +$696K +4.28% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 $88.6M $23.6M +$9.12M +62.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 $79.5M $28.7M +$14.9M +108% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
Q4 2018 $64.6M $20M +$3.27M +19.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 $61.3M $16.3M +$2.75M +20.3% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 $58.6M $14.5M -$239K -1.62% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 $58.8M $13.8M +$2.22M +19.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 $56.6M $16.7M +$4.03M +31.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-22
Q3 2017 $52.6M $13.5M +$1.37M +11.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-22
Q2 2017 $51.2M $14.8M +$3.76M +34.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-22
Q1 2017 $47.4M $11.6M -$234K -1.97% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-22
Q4 2016 $47.7M $12.7M +$4.45M +54.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-27
Q3 2016 $43.2M $12.2M +$8.04M +195% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-27
Q2 2016 $35.2M $11M +$8.25M +299% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-27
Q1 2016 $26.9M $11.9M +$9.58M +422% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-27
Q4 2015 $17.3M $8.2M Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 $4.12M Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 $2.76M Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 $2.27M Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23

HERON THERAPEUTICS, INC. /DE/ Annual Selling and Marketing Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $47.1M -$20.6M -30.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $67.6M -$14.9M -18% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $82.5M -$4.67M -5.35% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $87.2M +$23.3M +36.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 $63.9M -$25.9M -28.9% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-28
2019 $89.8M +$25.2M +38.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $64.6M +$8M +14.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
2017 $56.6M +$8.93M +18.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 $47.7M +$30.3M +175% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-22
2015 $17.3M +$8.64M +99.2% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-27
2014 $8.71M Jan 1, 2014 Dec 31, 2014 10-K 2017-02-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.